News & Updates
Filter by Specialty:

Neoadjuvant regorafenib, nivolumab, SCRT combination looks good for rectal cancer
Treatment with the combination of regorafenib, nivolumab, and short-course radiotherapy (SCRT) in the neoadjuvant setting has induced response in stage II-III rectal adenocarcinoma in the phase II REGINA trial, meeting the predefined statistical criteria.
Neoadjuvant regorafenib, nivolumab, SCRT combination looks good for rectal cancer
22 Aug 2024
Simple tests predict liver stiffness in people living with HIV, liver disease
A recent study has noted the excellent specificity and negative predictive value of FIB-4 and nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS) in diagnosing advanced fibrosis (AF, bridging fibrosis or cirrhosis) among people living with HIV (PWH).
Simple tests predict liver stiffness in people living with HIV, liver disease
22 Aug 2024
Does obesity raise mortality risk in COVID-19 patients?
Obesity does not appear to elevate the risk of death in critically ill patients with COVID-19, results of a study have shown. In addition, patients with BMI <25 kg/m2 have a higher rate of mortality than those with greater BMI levels.
Does obesity raise mortality risk in COVID-19 patients?
22 Aug 2024
Preventing exacerbations across a broad range of severe asthma patients
Preventing exacerbations across a broad range of severe asthma patients
22 Aug 2024
Anti-inflammatory diet supports brain health in people with cardiometabolic diseases
Among people with cardiometabolic diseases (CMD), diets with lower inflammatory potential contribute to larger gray matter and smaller white matter hyperintensity volumes, as well as reduced risk of dementia, according to a study.
Anti-inflammatory diet supports brain health in people with cardiometabolic diseases
21 Aug 2024
Cervical cancer: PFS advantage with pembrolizumab plus CCRT consistent in Asians
Patients with high-risk locally advanced cervical cancer in East Asia get progression-free survival (PFS) boost with pembrolizumab plus concurrent chemoradiotherapy (CCRT), similar to those observed in the overall population of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.